TARA Insider Trading

Insider Ownership Percentage: 12.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $987,261.16

Protara Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Protara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Protara Therapeutics Share Price & Price History

Current Price: $3.91
Price Change: Price Increase of +0.16 (4.27%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for TARA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$3.91Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Protara Therapeutics (NASDAQ:TARA)

38.13% of Protara Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TARA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$73Mbought$4.04MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
Protara Therapeutics logo
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Read More on Protara Therapeutics

Today's Range

Now: $3.91
Low: $3.76
High: $4.00

50 Day Range

MA: $4.09
Low: $3.36
High: $4.99

52 Week Range

Now: $3.91
Low: $1.60
High: $10.48

Volume

220,891 shs

Average Volume

762,496 shs

Market Capitalization

$143.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Who are the company insiders with the largest holdings of Protara Therapeutics?

Protara Therapeutics' top insider investors include:
  1. Opaleye Management Inc (Major Shareholder)
  2. Jacqueline Zummo (Insider)
Learn More about top insider investors at Protara Therapeutics.